Cibc World Markets Corp purchased a new position in shares of Organon & Co. (NYSE:OGN – Get Rating) during the 4th quarter, Holdings Channel.com reports. The fund purchased 29,905 shares of the company’s stock, valued at approximately $835,000.
Several other institutional investors have also recently made changes to their positions in OGN. Twin Tree Management LP bought a new position in shares of Organon & Co. during the 3rd quarter worth approximately $76,000. Barclays PLC boosted its stake in shares of Organon & Co. by 20.7% during the 3rd quarter. Barclays PLC now owns 170,870 shares of the company’s stock worth $3,997,000 after acquiring an additional 29,261 shares during the period. Douglas Lane & Associates LLC boosted its stake in shares of Organon & Co. by 102.6% during the 4th quarter. Douglas Lane & Associates LLC now owns 467,325 shares of the company’s stock worth $13,052,000 after acquiring an additional 236,693 shares during the period. Jump Financial LLC boosted its stake in shares of Organon & Co. by 42.2% during the 3rd quarter. Jump Financial LLC now owns 19,203 shares of the company’s stock worth $449,000 after acquiring an additional 5,701 shares during the period. Finally, Kendall Capital Management boosted its stake in shares of Organon & Co. by 11.0% during the 4th quarter. Kendall Capital Management now owns 18,522 shares of the company’s stock worth $517,000 after acquiring an additional 1,840 shares during the period. Institutional investors and hedge funds own 75.74% of the company’s stock.
Analysts Set New Price Targets
Separately, Raymond James began coverage on Organon & Co. in a research note on Wednesday, March 15th. They set an “outperform” rating and a $33.00 target price for the company.
Organon & Co. Price Performance
Organon & Co. (NYSE:OGN – Get Rating) last released its quarterly earnings results on Thursday, May 4th. The company reported $1.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.18 by ($0.10). The firm had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative return on equity of 119.00%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.65 earnings per share. Equities analysts anticipate that Organon & Co. will post 4.22 earnings per share for the current fiscal year.
Organon & Co. Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Monday, May 15th will be given a dividend of $0.28 per share. The ex-dividend date is Friday, May 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.48%. Organon & Co.’s payout ratio is 38.36%.
Organon & Co. Company Profile
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
- Get a free copy of the StockNews.com research report on Organon & Co. (OGN)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Get Rating).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.